Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
IPO Access
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
Been thinking about dividend stocks lately, and there's something worth discussing about the healthcare sector. Most companies don't even survive 20 years, right? So finding ones that actually deserve a forever hold is pretty rare. But I've noticed two healthcare names that seem to have the staying power and dividend consistency that makes them interesting for long-term income players.
First up is Bristol Myers Squibb. It's a solid pharma company with a massive drug portfolio spanning multiple therapeutic areas. Last year alone, they had 10 different products each pulling in over a billion in sales. Now, the thing everyone worries about with pharma is the patent cliff. BMY definitely faces some headwinds - Eliquis and Opdivo, their two biggest sellers, will lose exclusivity by the end of the decade. But here's the thing: they're not sitting idle. They've got a new subcutaneous version of Opdivo coming that's easier to administer, which extends that franchise. Plus their newer drug pipeline should fill the gaps as older products decline. This is how they've historically navigated these cycles, and there's no reason to think they'll stop now. The dividend is pretty attractive too - 4% forward yield with a 65.8% increase over the past decade. It's the kind of boring, steady play that quietly builds wealth if you're patient enough to reinvest.
Then there's Medtronic. Medical devices, not drugs, which is a different beast. They're making real innovations - pulsed field ablation for heart problems, and more recently the Hugo robotic surgery system for urology. The RAS market is still massively underpenetrated, so there's huge runway there. They're also spinning off their diabetes care unit, which should improve margins across the business. But what really stands out to me is the dividend track record. Medtronic has raised its payout for 48 consecutive years. That's not just impressive - that's a signal that this company can weather almost anything and keep performing. That kind of consistency is exactly what you want in a forever hold.
Both of these are the kind of stocks that fit the forever quotes mentality - not flashy, not going to 10x overnight, but the type of companies where you can set it and forget it. The dividend keeps flowing, the businesses adapt, and shareholders benefit over decades. That's the real wealth builder for most people.